Patents by Inventor Peter Bruenker

Peter Bruenker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20120244112
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: February 7, 2012
    Publication date: September 27, 2012
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES
    Publication number: 20120184718
    Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 27, 2010
    Publication date: July 19, 2012
    Applicant: Roche Glycart AG
    Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau, Sylvia Herter, Christoph Lampert, Ekkehard Moessner, Pablo Umana, Inja Waldhauer
  • HUMAN Fc GAMMA RECEPTOR III
    Publication number: 20110183354
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 1, 2011
    Publication date: July 28, 2011
    Inventors: ULRICH BRINKMANN, PETER BRUENKER, CLAUDIA FERRARA KOLLER, MARTIN LANZENDOERFER, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, ANNE ZECK
  • MULTISPECIFIC ANTIBODIES COMPRISING FULL LENGTH ANTIBODIES AND SINGLE CHAIN FAB FRAGMENTS
    Publication number: 20100256338
    Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 7, 2010
    Inventors: Ulrich Brinkmann, Peter Bruenker, Rebecca Croasdale, Christian Klein, Erhard Kopetzki, Ekkehard Moessner, Joerg Thomas Regula, Juergen Michael Schanzer, Jan Olaf Stracke, Pabio Umana
  • HUMAN Fc GAMMA RECEPTOR III
    Publication number: 20080248510
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 9, 2008
    Inventors: Ulrich Brinkmann, Peter Bruenker, Claudia Ferrara Koller, Martin Lanzendoerfer, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Anne Zeck
  • Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
    Publication number: 20040241817
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: January 22, 2004
    Publication date: December 2, 2004
    Applicant: GlycArt Biotechnology AG
    Inventors: Pablo Umana, Peter Bruenker, Claudia Ferrara, Tobias Suter